Athira Pharma (NSDQ:ATHA) announced that its lead development candidate, ATH-1017, had balanced baseline characteristics to date in two ongoing late-stage Alzheimer’s studies. Presenting the data at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston, the company’s chief medical officer Dr. Hans Moebius said that the baseline characteristics are consistent between the ACT-AD…
Athira Pharma CEO steps down in the wake of research misconduct allegations
Shares of Athira Pharma (NSDQ:ATHA) jumped 9.35% in mid-day trading after the company announced the resignation of embattled CEO Leen Kawas. Kawas will also give up her seat on the Bothell, Washington–based company’s board. Facing allegations that she doctored a series of images in research papers, Leen Kawas was placed on leave in June. Several…
Athira Pharma faces shareholder rights investigations
A growing number of law firms are investigating claims of securities fraud associated with Athira Pharma (NSDQ:ATHA), a clinical-stage biopharma focused on small molecules targeting neurodegeneration. Its lead therapeutic candidate, ATH-1017, targets dementia associated with Alzheimer’s and Parkinson’s. Law firms investigating potential securities fraud claims involving the company include the following: Ademi (Milwaukee). Block &…
Athira Pharma’s stock falls 39% after placing its CEO on leave
The Bothell, Wash.–based clinical-stage biopharma Athira Pharma (NSDQ:ATHA) is in a tailspin after the company’s board put Leen Kawas, the firm’s CEO, on temporary leave. The company’s stock closed the day at an all-time low of $11.15. The stock was valued as high as $34.25 on Dec. 31, 2020. The company had its initial public…